Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.74 |
| ▸ | STK10 | O94804 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | RET | P07949 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.74 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.74 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.74 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
| ▸ | HCK | P08631 | 1/20 | 0.74 |
| ▸ | KIT | P10721 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912166 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL20538934 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL18825560 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Alanine SCHEMBL2729838 | 0.97 | CYP3A4 (0.73) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL29354510 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227111 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227534 | 0.85 | KDR (0.83) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227589 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227112 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL17377930 | 0.85 | CYP3A4 (0.76) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| EP-4736872-A1 | TREATMENT METHOD AND USE OF PHARMACEUTICAL COMBINATION CONTAINING CONJUGATE | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736884-A1 | TREATMENT COMBINATION, AND USE THEREOF AND TREATMENT METHOD | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| EP-3541825-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4714966-A2 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | Cero Therapeutics Holdings, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KDR 3611/4885CYP3A4 4848/4885FGFR1 4425/4885 |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KDR 3544/4885CYP3A4 4822/4885FGFR1 4485/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | KDR 55/4885CYP3A4 4432/4885FGFR1 188/4885 |
| US-12600777-B2 | Combination therapies comprising antibody molecules to LAG-3 | IGSF11, IGLV6-57, CD2 | KDR 670/4885CYP3A4 4638/4885FGFR1 1677/4885 |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | KDR 4076/4885CYP3A4 783/4885FGFR1 1842/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | KDR 3732/4885CYP3A4 4840/4885FGFR1 4420/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | KDR 45/4885CYP3A4 4105/4885FGFR1 261/4885 |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CD47, TNFSF10, CD2 | KDR 712/4885CYP3A4 4572/4885FGFR1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.